As AI reshapes the pharmaceutical industry, it is opening a new chapter of opportunities in drug discovery, design, and development. To help accelerate the advent of Pharmaceutical Superintelligence, Insilico Medicine (03696.HK), a clinical-stage generative AI-driven drug discovery company, today announced that the Pharma.AI Webinar 2026 Q2 Summer Updates will take place on Tuesday, June 30, from 10:00 to 11:00 a.m. EST. Registration and event details are available at: https://insilico.zoom.us/webinar/register/6517804785683/WN_hxGDHR0bTAC8PoqiMhdeEA#/registration
The Pharma.AI 2026 Q2 Summer Update will highlight the continuous evolution of artificial intelligence within the life sciences. The upcoming event will address the focus on foundation models, articulate why domain-specific models remain essential to biological, chemical, and translational research, and illustrate how Pharma.AI integrates foundation models with scientific AI agents to create a unified, AI-driven paradigm for pharmaceutical R&D and scientific inquiry. It will also spotlight Insilico’s pioneering “AI trains AI” approach and expanding scientific discovery capabilities, showing how foundation models and AI agents can be more powerfully tailored for scientific research and drug discovery,accelerating the next generation of AI-driven decision-making systems.
“The world of AI has evolved at a breathtaking pace over the last few months, disrupting and rebuilding industries across multiple fronts. Our focus now is on moving beyond simple AI-driven tools toward a truly pharmaceutical superintelligence,” says Alex Aliper, PhD, President of Insilico Medicine.“With the continuous evolution of Pharma.AI, we are laying the groundwork for pharmaceutical superintelligence systems that can reason more effectively, seamlessly adapt to real scientific workflows, and drive meaningful impact across drug discovery and development.
“The world of AI has evolved at a breathtaking pace over the last few months, disrupting and rebuilding industries across multiple fronts. Our focus now is on moving beyond simple AI-driven tools toward a truly pharmaceutical superintelligence,” says Alex Aliper, PhD, President of Insilico Medicine.“With the continuous evolution of Pharma.AI, we are laying the groundwork for pharmaceutical superintelligence systems that can reason more effectively, seamlessly adapt to real scientific workflows, and drive meaningful impact across drug discovery and development.
Highlights at a Glance
Generative Biologics
Generative Biologics enables rapid, scalable sequence generation. Utilizing a suite of more than 10 generative and predictive models coupled with physics-based algorithms, the platform delivers novel, structurally diverse, and high-affinity biologics against complex epitopes and traditionally hard-to-drug targets. This streamlined workflow produces optimized binder candidates in under 72 hours, significantly accelerating the early-stage discovery pipeline.
The latest platform update introduces two powerful new workflows designed to accelerate biologics discovery and optimization. Batch MDflow brings high-throughput Molecular Dynamics simulations to the platform, enabling researchers to screen and evaluate multiple structures in parallel with fully automated setup and preprocessing. Interactive Optimization gives scientists direct control over binder engineering, allowing them to explore site-directed mutations, identify variants with improved affinity and stability, and rapidly combine beneficial changes into next-generation lead candidates – all within a single, intuitive workflow.
The latest platform update introduces two powerful new workflows designed to accelerate biologics discovery and optimization. Batch MDflow brings high-throughput Molecular Dynamics simulations to the platform, enabling researchers to screen and evaluate multiple structures in parallel with fully automated setup and preprocessing. Interactive Optimization gives scientists direct control over binder engineering, allowing them to explore site-directed mutations, identify variants with improved affinity and stability, and rapidly combine beneficial changes into next-generation lead candidates – all within a single, intuitive workflow.
Chemistry42
Chemistry42 is Insilico Medicine's AI-driven platform for the design and discovery of novel small molecules. By combining generative model ensembles with advanced physics-based methods, it helps researchers create and optimize compounds across hit identification, hit-to-lead, and lead optimization programs.
This update introduces new capabilities across key Chemistry42 Apps, with improvements to Reward Models, a new kinase selectivity panel in Property Profiling, and multiple updates to Alchemistry and MDFlow. Finally, we'll preview Chemistry42's models and tools as MCP Servers — powering a new prompt-driven mode that unlocks far broader control over the platform's engine, putting state-of-the-art chemistry tools and models directly in your prompt window.
This update introduces new capabilities across key Chemistry42 Apps, with improvements to Reward Models, a new kinase selectivity panel in Property Profiling, and multiple updates to Alchemistry and MDFlow. Finally, we'll preview Chemistry42's models and tools as MCP Servers — powering a new prompt-driven mode that unlocks far broader control over the platform's engine, putting state-of-the-art chemistry tools and models directly in your prompt window.
PandaOmics
PandaOmics is Insilico Medicine’s AI-driven platform for biological target discovery and drug program evaluation. In this release, PandaOmics introduces PandaClaw, an advanced autonomous AI agent functioning as an intelligent orchestration layer to streamline and scale complex biological analyses. Expanding beyond initial target identification, PandaClaw automates end-to-end analytical workflows, from dynamic planning and execution to critique and report generation. By leveraging curated bioinformatic tools and specialized scientific skills, it provides comprehensive support for Target Evaluation (assessing druggability metrics and the competitive pharmacological landscape) and Target-Disease Evaluation (elucidating Mechanisms of Action). Spanning applications from robust multi-group expression comparisons and gene signature analyses to the exploration of aging biology through Longevity Lobster, PandaClaw seamlessly converts fragmented multi-omic datasets and text data into actionable insights, bridging computational predictions with concrete, literature-backed therapeutic strategies.
MMAI Gym
The MMAI Gym for Science is Insilico Medicine's solution for training and benchmarking foundation models. The MMAI Gym adapts any causal foundation model into a high-performance engine for drug discovery through multi-task SFT+RFT with domain-specific reasoning. It can produce both a SOTA domain specialist and a "Single-Model-Does-It-All" generalist that masters property and ADMET prediction, molecular optimization, retrosynthesis, functional-group reasoning, target identification, and clinical trial-outcome prediction. Models trained in the MMAI Gym deliver up to a 10× performance increase over their baselines and surpass both task-specific specialists and frontier LLMs. Through the MMAI Gym, you can train and evaluate your own models, or license checkpoints already trained in the Gym.
Join Insilico Medicine for our exclusive Pharma AI Summer Event, where we cut through the generic AI hype to highlight real-world, industrial-strength execution.
This virtual webinar brings together pharmaceutical executives, computational biologists, and medicinal chemists to explore the frontier of Pharmaceutical Superintelligence (PSI).
This virtual webinar brings together pharmaceutical executives, computational biologists, and medicinal chemists to explore the frontier of Pharmaceutical Superintelligence (PSI).